Jim Fink is chief investment strategist for Jim Fink’s Options for Income and Roadrunner Stocks. He has traded options for more than 20 years and generated personal profits of more than $5 million. Jim also serves as an investment analyst at Investing Daily’s flagship investing publication, Personal Finance.
Hopelessly overeducated, Jim holds a bachelor’s degree from Yale University, a master’s degree from Harvard’s Kennedy School of Government, a law degree from Columbia University, and an MBA from the University of Virginia’s Darden School of Business. For good measure, he has been a member of the Illinois and D.C. bars and is a CFA charterholder.
Prior to joining Investing Daily, and when not incurring student loans hiding out in academe, Jim practiced telecommunications regulatory law for nine years until he realized that he made more money trading stock options than writing briefs. After attending business school, Jim switched gears to the investment realm full-time, working for a university endowment, a private wealth management firm, an insurance and financial planning company, and as a Senior Analyst for an online investment newsletter service that encourages the wearing of funny hats.
A possible but unlikely descendant of legendary brawler and boatman Mike Fink, Jim defies his heritage, believing that investing success requires patience and analysis, not swashbuckling bravado. Besides his passion for analyzing and writing about stocks, Jim likes to hike in the desert Southwest, vacation in Las Vegas, play tennis, and feed his toddler son Cheerios.
In today’s market, understanding what a company is really worth is more essential than ever.
Small-cap stocks often underperform at this time of year, but they come roaring back.
It’s important to consider foreign stocks in order to maximize your returns.
A recent Roadrunner call shows the importance of knowing when to sell.
G-III Apparel keeps its winning streak alive.
It’s not yet time yet to turn bearish on stocks.
A favorable court decision leads to a one-day jump of more than 28 percent.
The recent trend toward buyouts of small-cap biotech companies.
They don’t just grow your nest egg – they can prolong its life.
Is It Time to Go for Value or Momentum?